Ketamine-Induced Unresponsiveness Shows a Harmonic Shift from Global to Localised Functional Organisation - Van Maldegem M; Vohryzek J; Atasoy S; Alnagger N; Cardone P; Bonhomme V; Vanhaudenhuyse A; Demertzi A; Jaquet O; Bahri MA; Kringelbach ML; Stamatakis EA; et al. (bioRxiv, 2024)

Acute Effects of Hallucinogens on Functional Connectivity: Psilocybin and Salvinorin-A. - Bagdasarian FA; Hansen HD; Chen J; Yoo CH; Placzek MS; Hooker JM; Wey HY. (2024)

Psilocybin: Medicine for My Soul. Relief from Emotional and Spiritual Pain as a Hospice Nurse Diagnosed with Cancer. - Clark MP. (2024)

Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First Responders - Empower Research Inc (ClinicalTrials.gov, 2024)

Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension. - Jones GM; Ricard JA; Nock MK. (2024)

Increased reactivity of the paraventricular nucleus of the hypothalamus and decreased threat responding in male rats following psilocin administration. - Effinger DP; Hoffman JL; Mott SE; Magee SN; Quadir SG; Rollison CS; Toedt D; Echeveste Sanchez M; High MW; Hodge CW; Herman MA. (2024)

Effects of psilocybin on uncertain punishment learning. - Jacobs DS; Bogachuk AP; Le Moing CL; Moghaddam B. (2024)

Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine. - Barnett BS; Koons CJ; Van den Eynde V; Gillman PK; Bodkin JA. (2024)

Rapid and prolonged antidepressant and antianxiety effects of psilocybin, lysergic acid diethylamide, ayahuasca, and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis of randomized controlled trials - Fluyau D; Kailasam VK; Revadigar N. (medRxiv, 2024)

The cyclical revival of psychedelics in psychiatric treatment. - Appiani FJ; Caroff SN. (2024)

Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs. - Guo Q; Guo L; Wang Y; Shang S. (2024)

Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion - Johns Hopkins University (ClinicalTrials.gov, 2024)

Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study. - Korthuis PT; Hoffman K; Wilson-Poe AR; Luoma JB; Bazinet A; Pertl K; Morgan DL; Cook RR; Bielavitz S; Myers R; Wolf RC; McCarty D; et al. (2024)

Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities. - Kanis FC; Broude CN; Hellwarth EB; Gibbons WJ; Sen AK; Adams AM; Wang X; Jones JA. (2024)

Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study - Imperial College London (ClinicalTrials.gov, 2024)

Licit use of illicit drugs for treating depression: the pill and the process. - Torrado Pacheco A; Moghaddam B. (2024)

A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy? - Downey AE; Bradley ER; Lerche AS; O'Donovan A; Krystal AD; Woolley J. (2024)

Impact of Psilocybin on Peripheral Cytokine Production. - DiRenzo D; Barrett FS; Perin J; Darrah E; Christopher-Stine L; Griffiths RR. (2024)

Comparing Cannabis Use Motivations and Dependence Across Regular Cannabis Users Who Have or Have Not Recently Used Psilocybin. - Stanger MK; Soffer HO; Bryan AD; Skrzynski CJ. (2024)

Increased 5-HT2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics - Ippolito A; Vasudevan S; Hurley S; Gilmour G; Westhorpe F; Churchill G; Sharp T. (bioRxiv, 2024)

Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. - Polito V; Liknaitzky P. (2024)

Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience - Nicholas CR; Banks MI; Lennertz RL; Wenthur CJ; Krause BM; Riedner BA; Smith RF; Hutson PR; Sauder CJ; Dunne JD; Roseman L; Raison CL. (bioRxiv, 2024)

Effects of psilocin and psilocybin on human 5-HT4 serotonin receptors in atrial preparations of transgenic mice and humans. - Neumann J; Dimov K; Azatsian K; Hofmann B; Gergs U. (2024)

Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder. - Szafoni S; Gręblowski P; Grabowska K; Więckiewicz G. (2024)

Neural mechanisms of psychedelic visual imagery. - Stoliker D; Preller KH; Novelli L; Anticevic A; Egan GF; Vollenweider FX; Razi A. (2024)

Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies - Petrovitch D; Mitchell SM; Van Allen J; Littlefield AK. (PsyArXiv, 2024)

A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder - University of Sydney (ClinicalTrials.gov, 2024)

Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies (PsyArXiv, 2024)

5-MeO-DMT in the complete resolution of the consequences of chronic, severe sexual abuse in early childhood-a retrospective case study - Turkia M. (PsyArXiv, 2024)

Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA - Calder A; Hasler G. (PsyArXiv, 2024)

5-MeO-DMT in the complete resolution of the consequences of chronic, severe sexual abuse in early childhood-a retrospective case study (PsyArXiv, 2024)

Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA (PsyArXiv, 2024)

The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. - Ramos L; Vicente SG. (2024)

Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis? - Andrews CM; Hall W; Humphreys K; Marsden J. (2024)

Study protocol for "Psilocybin in patients with fibromyalgia: brain biomarkers of action". - Bornemann J; Close JB; Ahmad K; Barba T; Godfrey K; Macdonald L; Erritzoe D; Nutt D; Carhart-Harris R. (2024)

The molecular structure, vibrational spectra, solvation effect, non-covalent interactions investigations of psilocin. - Holikulov U; Kazachenko AS; Issaoui N; Kazachenko AS; Raja M; Al-Dossary OM; Xiang Z. (2024)

Effect of oral tryptamines on the gut microbiome of rats-a preliminary study. - Xu M; Kiss AJ; Jones JA; McMurray MS; Shi H. (2024)

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity. - Wang CK; Kim G; Aleksandrova LR; Panenka WJ; Barr AM. (2024)

Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms. - Rakoczy RJ; Runge GN; Sen AK; Sandoval O; Wells HG; Nguyen Q; Roberts BR; Sciortino JH; Gibbons WJ; Friedberg LM; Jones JA; McMurray MS. (2024)

Psilocybin in Bipolar II Study Provides Preliminary Data on Safety. - Yaden DB; Gukasyan N; Nayak SM. (2024)

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial. - Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T. (2024)

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases - Haniff Z; Bocharova M; Mantingh T; Rucker J; Velayudhan L; Taylor D; Young A; Aarsland D; Vernon A; Thuret S. (2024)

Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety. - Fried EI; Cristea IA; Naudet F. (2024)

Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-Reply. - Aaronson ST; van der Vaart A; Sackeim HA. (2024)

At the Forefront: Social Workers' Role in Psilocybin Treatment for Depression and Substance Misuse. - Parker C; Wood BM. (2024)

Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats - Floris G; Dabrowski KR; Zanda MT; Daws SE. (bioRxiv, 2024)

Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT - Vohryzek J; Luppi A; Atasoy S; Deco G; Timmermann C; Carhart-Harris RL; Kringelbach ML. (bioRxiv, 2024)

Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review. - Chisamore N; Johnson D; Chen MJQ; Offman H; Chen-Li D; Kaczmarek ES; Doyle Z; McIntyre RS; Rosenblat JD. (2024)

Psilocybin decreases neural responsiveness and increases functional connectivity while preserving pure-tone frequency selectivity in mouse auditory cortex. - Brockett AT; Francis NA. (2024)

Therapeutic Psilocybin's Adverse Effects Mostly Resolved Within 2 Days. - Harris E (JAMA, 2024)

Medical Uses and Adverse Effects of Psilocybin. - Ghaznavi S; Bernardez LM; Stern TA. (2024)

Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report. - Chopra H; Furnish T; Verduzco-Gutierrez M; Jevotovsky DS; Castellanos J. (2024)

Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related Psychopathology - McGovern H; Wellman N; Hutchinson B; Oestreich LKL; Cooper SE; Fonzo G; Doss M. (PsyArXiv, 2024)

Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related Psychopathology (PsyArXiv, 2024)

Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression - Aboharb F; Davoudian PA; Shao L; Liao C; Rzepka GN; Wojtasiewicz C; Indajang J; Dibbs M; Rondeau J; Sherwood AM; Kaye AP; Kwan AC. (bioRxiv, 2024)

On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders. - Hoyer D. (Authorea Preprints, 2024)

Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder. - Ehrenkranz R; Agrawal M; Penberthy JK; Yaden DB. (2024)

Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis. - Fang Q; Chan VKY; Chan SSM; Jiao Y; Wang J; Li X. (2024)

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial. - Bhagavan C; Glue P; Evans W; Reynolds L; Turner T; King C; Russell BR; Morunga E; Mills JL; Layton G; Menkes DB. (2024)

Psychedelic therapy in depression and substance use disorders. - Korkmaz ND; Cikrikcili U; Akan M; Yucesan E. (2024)

A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)- and psilocybin-related death in Australia. - Darke S; Duflou J; Peacock A; Farrell M; Hall W; Lappin J. (2024)

A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient. - Morris SL. (2024)

The influence of psilocybin on subconscious and conscious emotional learning. - Casanova AF; Ort A; Smallridge JW; Preller KH; Seifritz E; Vollenweider FX. (2024)

Stutterers' experiences on classic psychedelics: A preliminary self-report study. - Jackson ES; Goldway N; Gerlach-Houck H; Gold ND. (2024)

Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy - Marinis J; Clarke ST; Bedi G. (PsyArXiv, 2024)

Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy (PsyArXiv, 2024)

Psilocybin increases optimistic engagement over time: computational modelling of behavior in rats - Fisher EL; Smith R; Corcoran AW; Milton LK; Conn K; Hohwy J; Foldi CJ. (bioRxiv, 2024)

RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine. - Bryson N; Alexander R; Asnis-Alibozek A; Ehlers MD. (2024)

Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians. - Vina SM. (2024)

Structural characterization and comparative analysis of polymorphic forms of psilocin (4-hy-droxy-N,N-di-methyl-tryptamine). - Zeller M; Parent S; Schultheiss N. (2024)

Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review. - Yu Z; Burback L; Winkler O; Xu L; Dennett L; Vermetten E; Greenshaw A; Li XM; Milne M; Wang F; Cao B; Winship IR; et al. (2024)

Psychedelics Use and the Risk of Reduced Formal Mental Health Care - Viña S. (Research Square, 2024)

Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution. - Jeffrey JK; Weintraub MJ; Grob CS. (2024)

An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients - Nova Mentis Life Science Corp (ClinicalTrials.gov, 2024)

Structural pharmacology and therapeutic potential of 5-methoxytryptamines. - Warren AL; Lankri D; Cunningham MJ; Serrano IC; Parise LF; Kruegel AC; Duggan P; Zilberg G; Capper MJ; Havel V; Russo SJ; Sames D; et al. (2024)

Advancements in Psychoactive Alkaloid Delivery, Neuroenhancement, and Psychedelic Therapies: Exploring the Frontiers of Modern Pharmacology. - Kargbo RB. (2024)

Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial - University of Calgary (ClinicalTrials.gov, 2024)

What is needed for the roll-out of psychedelic treatments? - Xenakis SN; Shannon SM. (2024)

Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study. - Nayak SM; White SH; Hilbert SN; Lowe MX; Jackson H; Griffiths RR; Garcia-Romeu A; Yaden DB. (2024)

Psilocybin facilitates fear extinction: importance of dose, context, and serotonin receptors - Woodburn SC; Levitt CM; Koester AM; Kwan AC. (bioRxiv, 2024)

Effects of Classical Psychedelics on Implicit and Explicit Emotional Empathy and Cognitive Empathy: A Meta-analysis of MET task - Olami A; Peled-Avron L. (bioRxiv, 2024)

EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. (2024)

PSYCHEDELIC PSILOCYBIN-ASSISTED THERAPY REDUCES DEPRESSIVE SYMPTOMS IN ADULTS WITH CANCER AND DEPRESSION. (2024)

Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy. - Schmid Y; Bershad AK (Biological psychiatry. Cognitive neuroscience and neuroimaging, 2024)

The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis. - Shafiee A; Arabzadeh Bahri R; Rafiei MA; Esmaeilpur Abianeh F; Razmara P; Jafarabady K; Amini MJ (Journal of psychopharmacology (Oxford, England), 2024)

Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review. - Romeo B; Kervadec E; Fauvel B; Strika-Bruneau L; Amirouche A; Verroust V; Piolino P; Benyamina A (Psychiatry research, 2024)

Psilocybin for depression. - De Giorgi R; Ede R. (2024)

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. - Metaxa AM; Clarke M. (2024)

New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity. - Ruan Y; Yuan R; He J; Jiang Y; Chu S; Chen N. (2024)

Structural characterization and comparative analysis of polymorphic forms of psilocin (4-hydroxy-N,N-dimethyltryptamine) - Zeller M; Parent S; Schultheiss N. (2024)

Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. - Sakai K; Bradley ER; Zamaria JA; Agin-Liebes G; Kelley DP; Fish A; Martini V; Ferris MC; Morton E; Michalak EE; O'Donovan A; Woolley JD. (2024)

In vitro and in vivo metabolism of psilocybin's active metabolite psilocin. - Thomann J; Kolaczynska KE; Stoeckmann OV; Rudin D; Vizeli P; Hoener MC; Pryce CR; Vollenweider FX; Liechti ME; Duthaler U. (2024)

In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials. - Soliman PS; Curley DE; Capone C; Eaton E; Haass-Koffler CL. (2024)

Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice. - Zhao X; Du Y; Yao Y; Dai W; Yin Y; Wang G; Li Y; Zhang L. (2024)

Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon. - Bellman V. (2024)

Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms. - Conn K; Milton LK; Huang K; Munguba H; Ruuska J; Lemus MB; Greaves E; Homman-Ludiye J; Oldfield BJ; Foldi CJ. (2024)

Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2024)

The 'PSILAUT' protocol: an experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin. - Whelan TP; Daly E; Puts NA; Smith P; Allison C; Baron-Cohen S; Malievskaia E; Murphy DGM; McAlonan GM. (2024)

Genetic regulation of L-tryptophan metabolism in Psilocybe mexicana supports psilocybin biosynthesis. - Seibold PS; Dörner S; Fricke J; Schäfer T; Beemelmanns C; Hoffmeister D. (2024)

Do undergraduates’ views of psychedelics relate to the context for psychedelic use? - Petrovitch D; Van Allen J; Mitchell SM; Littlefield AK. (PsyArXiv, 2024)

300 Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: An fMRI pilot study - Pagni B; Petridis P; Podrebarac S; Grinband J; Claus E; Bogenschutz M. (2024)

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians. - Downey AE; Chaphekar AV; Woolley J; Raymond-Flesch M. (2024)

Do undergraduates’ views of psychedelics relate to the context for psychedelic use? (PsyArXiv, 2024)

Author Correction: Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation. - Singer B; Meling D; Hirsch-Hoffmann M; Michels L; Kometer M; Smigielski L; Dornbierer D; Seifritz E; Vollenweider FX; Scheidegger M. (2024)

The selective 5-HT2A receptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents - Jensen AA; Cecchi CR; Hibicke M; Bach AH; Kaadt E; Märcher-Rørsted E; Nichols CD; Elfving B; Kristensen JL. (bioRxiv, 2024)

Psilocybin reduces functional connectivity and the encoding of spatial information by neurons in mouse retrosplenial cortex - Ivan V; Tomas-Cuesta D; Esteves I; Luczak A; Mohajerani M; McNaughton B; Gruber A. (Authorea Preprints, 2024)

Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists. - M Ro Rsted E; Jensen AA; Smits G; Frydenvang K; Kristensen JL. (2024)

Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions. - Tipado Z; Kuypers KPC; Sorger B; Ramaekers JG. (2024)

The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study - Section for Affective Disorders; Northern Stockholm Psychiatry (ClinicalTrials.gov, 2024)

Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: Interaction with serotonergic receptor modulators. - Lerer E; Botvinnik A; Shahar O; Grad M; Blakolmer K; Shomron N; Lotan A; Lerer B; Lifschytz T. (2024)

Palliative care patients' attitudes and openness towards psilocybin-assisted psychotherapy for existential distress. - Wang JR; Mendez Araque SJ; Micciche G; McMillan A; Coughlin E; Mattiola R; English D; Kaliebe K. (2024)

Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder. - Köhne S; Hillemacher T; Glahn A; Bach P. (2024)

Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. - Sloshower J; Zeifman RJ; Guss J; Krause R; Safi-Aghdam H; Pathania S; Pittman B; D'Souza DC. (2024)

Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens. - Rahman SM; Salem Y; Hussain A. (2024)

A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia. - Hatfield SP; Thornton NL; Greenstien K; Glozier N. (2024)

A dual-receptor model of serotonergic psychedelics - Juliani A; Chelu V; Graesser L; Safron A. (bioRxiv, 2024)

Psychedelics and the 'inner healer': Myth or mechanism? - Peill J; Marguilho M; Erritzoe D; Barba T; Greenway KT; Rosas F; Timmermann C; Carhart-Harris R. (2024)

The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov. - Norring SA; Spigarelli MG. (2024)

Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor. - Harari R; Chatterjee I; Getselter D; Elliott E. (2024)

Mechanisms of therapeutic change after psychedelic treatment in OCD. - Maloney G; Ching T; Kichuk SA; Pittenger C; Kelmendi B. (2024)

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. - Haniff ZR; Bocharova M; Mantingh T; Rucker JJ; Velayudhan L; Taylor DM; Young AH; Aarsland D; Vernon AC; Thuret S. (2024)

Dynamic Functional Hyperconnectivity After Psilocybin Intake Is Primarily Associated With Oceanic Boundlessness. - Mortaheb S; Fort LD; Mason NL; Mallaroni P; Ramaekers JG; Demertzi A. (2024)

Cultivation, chemistry, and genome of Psilocybe zapotecorum. - Miller DR; Jacobs JT; Rockefeller A; Singer H; Bollinger IM; Conway J; Slot JC; Cliffel DE. (2024)

[Psychedelic psychiatry]. - López E; Yngwe H; Beckman M; Tiger M; Hieronymus F; Lundberg J. (2024)

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2) - University Health Network; Toronto (ClinicalTrials.gov, 2024)

Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. - Schindler EAD; Sewell RA; Gottschalk CH; Flynn LT; Zhu Y; Pittman BP; Cozzi NV; D'Souza DC. (2024)

Inhibition of cytochrome P450 3A4 enzyme activity by alkaloid psilocin from magic mushrooms: potential for drug interactions - Wilson Lavonne; Babumon Muthiramalil T.; Irvine William; Morrison Isaac; Foster Kimberly; Delgoda Rupika (Drug Metabolism and Pharmacokinetics, 2024)

Evidence versus expectancy: the development of psilocybin therapy. - Rucker JJ. (2024)

Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom. - Simonsson O; Osika W; Stenfors CUD; Goldberg SB; Honk L; Hendricks PS (Psychological medicine, 2024)

Magic mushroom and zebrafish: A new recipe? - Gerlai R (Lab animal, 2024)

The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience. - Tolle HM; Farah JC; Mallaroni P; Mason NL; Ramaekers JG; Amico E. (2024)

Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. - Yerubandi A; Thomas JE; Bhuiya NMMA; Harrington C; Villa Zapata L; Caballero J. (2024)

The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action. - Tap SC. (2024)

The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics. - Wilkes R; Roberts DM; Liknaitzky P; Brett J. (2024)

Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. - Le GH; Wong S; Badulescu S; Au H; Di Vincenzo JD; Gill H; Phan L; Rhee TG; Ho R; Teopiz KM; Kwan ATH; Rosenblat JD; et al. (2024)

Use of Prescribed and Non-Prescribed Treatments for Cluster Headache in a Swedish Cohort. - Smedfors G; Jennysdotter Olofsgård F; Steinberg A; Waldenlind E; Ran C; Belin AC. (2024)

Methyl transfer in psilocybin biosynthesis. - Hudspeth J; Rogge K; Dörner S; Müll M; Hoffmeister D; Rupp B; Werten S. (2024)

Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. - Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; et al. (2024)

Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation. - Singer B; Meling D; Hirsch-Hoffmann M; Michels L; Kometer M; Smigielski L; Dornbierer D; Seifritz E; Vollenweider FX; Scheidegger M. (2024)

Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. - Erritzoe D; Barba T; Spriggs MJ; Rosas FE; Nutt DJ; Carhart-Harris R. (2024)

A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer - University of Utah (ClinicalTrials.gov, 2024)

Ethical considerations for psychedelic-assisted therapy in military clinical settings. - Hoener S; Wolfgang A; Nissan D; Howe E. (2024)

Five New Species of Gymnopilus from Xizang Autonomous Region of China and Surrounding Areas. - Yang WQ; Li JX; He MQ; Wang SH; Zhu XY; Phurbu D; Yun JM; Zhao RL. (2024)

Safety pharmacology of acute psilocybin administration in healthy participants. - Straumann I; Holze F; Becker AM; Ley L; Halter N; Liechti ME. (2024)

Problems of Qualification of Trafficking in Plants and Plant Parts Containing Psychoactive Substances and Mushrooms Containing Psilocybin and (or) Psilocin - Kulikov Aleksandr V.; Zheleznyak Ilya Yu. (Drug control, 2024)

The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. - Levin AW; Lancelotta R; Sepeda ND; Gukasyan N; Nayak S; Wagener TL; Barrett FS; Griffiths RR; Davis AK. (2024)

UK medical students' self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study. - Song-Smith C; Jacobs E; Rucker J; Saint M; Cooke J; Schlosser M. (2024)

The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item. - Strickland JC; Garcia-Romeu A; Johnson MW. (2024)

Preadministration of Lorazepam Reduces Efficacy and Longevity of Antidepressant-Like Effect from a Psychedelic. - Hibicke M; Billac G; Nichols CD. (2024)

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain. - Robinson CL; Fonseca ACG; Diejomaoh EM; D'Souza RS; Schatman ME; Orhurhu V; Emerick T. (2024)

Neuroimaging features of psilocybin-induced toxic-metabolic encephalopathy in an adolescent. - Ho C; Crawford JR. (2024)

Where do the symptoms come from in depression? Topography and dynamics matter. - Çatal Y; Northoff G. (2024)

A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder. - Velit-Salazar MR; Shiroma PR; Cherian E. (2024)

Screening and confirmation of psilocin, mitragynine, phencyclidine, ketamine and ketamine metabolites by liquid chromatography-tandem mass spectrometry. - Wood ME; Brown GJ; Karschner EL; Seither JZ; Brown JT; Knittel JL; Walterscheid JP. (2024)

Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview. - Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS. (2024)

Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin. - Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS. (2024)

American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A7-Year Follow-Up Survey. - Barnett BS; Arakelian M; Beebe D; Ontko J; Riegal C; Siu WO; Weleff J; Pope HG (Psychedelic medicine (New Rochelle, N.Y.), 2024)

Psilocybin and the Development of Serotonin Toxicity. - Amarnani AD; Free MF; Baweja R. (2024)

A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder. - Norred MA; Zuschlag ZD; Hamner MB. (2024)

Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. - Copa D; Erritzoe D; Giribaldi B; Nutt D; Carhart-Harris R; Tagliazucchi E. (2024)

Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics? - Hashimoto K. (2024)

Psilocybin Exposures Reported to U.S. Poison Centers: National Trends Over a Decade. - Farah R; Kerns AF; Murray AC; Holstege CP. (2024)

The Temporal Trajectory of the Psychedelic Mushroom Experience Mimics the Narrative Arc of the Hero’s Journey - Brouwer A; Brown JK; Erowid E; Erowid F; Thyssen S; Raison CL; Carhart-Harris RL. (Research Square, 2024)

Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights. - Laabi S; LeMmon C; Vogel C; Chacon M; Jimenez VM. (2024)

Prefrontal Electrophysiological Biomarkers and Mechanism-Based Drug Effects in a Rat Model of Alcohol Addiction - Habelt B; Afanasenkau D; Schwarz C; Domanegg K; Kuchar M; Werner C; Minev IR; Spanagel R; Meinhardt MW; Bernhardt N. (Research Square, 2024)

Synthesis and bioactivity of psilocybin analogues containing a stable carbon-phosphorus bond. - Vandevelde M; Simoens A; Vandekerckhove B; Stevens C. (2024)

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects. - Bhatt KV; Weissman CR. (2024)

Expectancy Effects in Psychedelic Trials. - Szigeti B; Heifets BD. (2024)

Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain. - Shahar O; Botvinnik A; Shwartz A; Lerer E; Golding P; Buko A; Hamid E; Kahn D; Guralnick M; Blakolmer K; Wolf G; Lotan A; et al. (2024)

Development of a digital intervention for psychedelic preparation (DIPP). - McAlpine RG; Sacchet MD; Simonsson O; Khan M; Krajnovic K; Morometescu L; Kamboj SK. (2024)

The Intersection of Mental Health and Sexual and Gender Minority Identities for Older Adults Living with Human Immunodeficiency Virus: A Narrative Review. - Agor D; Knettel BA; Daici K; Meanley S. (2024)

Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. - Ching THW; Amoroso L; Bohner C; D'Amico E; Eilbott J; Entezar T; Fitzpatrick M; Fram G; Grazioplene R; Hokanson J; Jankovsky A; Kichuk SA; et al. (2024)

Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain. - Frautschi PC; Singh AP; Stowe NA; Yu JJ. (2024)

Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. - Fang S; Yang X; Zhang W. (2024)

Brain dynamics predictive of response to psilocybin for treatment-resistant depression. - Vohryzek J; Cabral J; Lord LD; Fernandes HM; Roseman L; Nutt DJ; Carhart-Harris RL; Deco G; Kringelbach ML. (2024)

New evidence for flexible psilocybin dosing in patients with treatment-resistant depression. - Aaronson ST; Kozak Z. (2024)

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. - Rosenblat JD; Meshkat S; Doyle Z; Kaczmarek E; Brudner RM; Kratiuk K; Mansur RB; Schulz-Quach C; Sethi R; Abate A; Ali S; Bawks J; et al. (2024)

Natural Product Synthesis in the 21st Century: Beyond the Mountain Top. - Shenvi RA. (2024)

Pioneering Methods in Brain Optimization and Mental Health Treatment. - Kargbo RB. (2024)

Psilocybin induces dose-dependent changes in functional network organization in rat cortex - Silverstein BH; Kolbman N; Nelson A; Liu T; Guzzo P; Gilligan J; Lee U; Mashour GA; Vanini G; Pal D. (bioRxiv, 2024)

Psychedelic Microdosing among Young Adults from Southern California. - Harlow AF; Hendricks PS; Leventhal AM; Barrington-Trimis JL. (2024)

Repeat Dosing of Psilocybin in Headache Disorders - Yale University (ClinicalTrials.gov, 2024)

Development and psychometric validation of a novel scale for measuring 'psychedelic preparedness'. - McAlpine RG; Blackburne G; Kamboj SK. (2024)

Effects of DMT on mental health outcomes in healthy volunteers. - Timmermann C; Zeifman RJ; Erritzoe D; Nutt DJ; Carhart-Harris RL. (2024)

Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study. - Pagni BA; Petridis PD; Podrebarac SK; Grinband J; Claus ED; Bogenschutz MP. (2024)

Psychedelics and sexual functioning: a mixed-methods study. - Barba T; Kettner H; Radu C; Peill JM; Roseman L; Nutt DJ; Erritzoe D; Carhart-Harris R; Giribaldi B. (2024)

National and regional trends in seizures of shrooms (psilocybin) in the United States, 2017-2022. - Palamar JJ; Fitzgerald ND; Carr TH; Rutherford C; Keyes KM; Cottler LB. (2024)

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. - Breeksema JJ; Niemeijer A; Krediet E; Karsten T; Kamphuis J; Vermetten E; van den Brink W; Schoevers R. (2024)

Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists. - Sandbrink JD; Johnson K; Gill M; Yaden DB; Savulescu J; Hannikainen IR; Earp BD. (2024)

A Systematic Review of Interventions for Demoralization in Patients with Chronic Diseases. - Dong L; Li L; Wu Y; Zhao X; Zhong H; Cheng X; Liu L; Cheng C; Ouyang M; Tao L. (2024)

Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles - Rogers SA; Heller EA; Corder G. (bioRxiv, 2024)

A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use - Johns Hopkins University (ClinicalTrials.gov, 2024)

Effects of hallucinogenic drugs on the human heart. - Neumann J; Dhein S; Kirchhefer U; Hofmann B; Gergs U. (2024)

The development of psilocybin therapy for treatment-resistant depression: an update. - Borissova A; Rucker JJ. (2024)

The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis. - Sicignano D; Hernandez AV; Schiff B; Elmahy N; White CM (Current medical research and opinion, 2024)

Letter to the Editor: Will Psilocybin-Assisted Therapy Reduce the Incidence of Medical Assistance in Dying? - Cho M; Rosenbaum D; Schneider E; Hales S. (2024)

Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways. - Sinha JK; Trisal A; Ghosh S; Gupta S; Singh KK; Han SS; Mahapatra M; Abomughaid MM; Abomughayedh AM; Almutary AG; Iqbal D; Bhaskar R; et al. (2024)

Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile. - Holze F; Singh N; Liechti ME; D'Souza DC. (2024)

Psychedelic psilocybin-assisted therapy reduces depressive symptoms in adults with cancer and depression. (2024)

Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study. - Borkel LF; Rojas-Hernández J; Henríquez-Hernández LA; Santana Del Pino Á; Quintana-Hernández DJ. (2024)